Also known as: Imitrex Succinate; Sumatriptan Hydrogen Succinate
Sumatriptan Succinate is the succinate salt form of Sumatriptan, a selective serotonin receptor agonist for acute migraine treatment. The succinate salt is widely used in commercial tablet and injectable formulations. Mediocon Inc supplies pharmaceutical-grade Sumatriptan Succinate conforming to IP / BP / EP / USP specifications.
As the commercially preferred salt form, Sumatriptan Succinate offers excellent aqueous solubility and stability, making it suitable for both oral tablets and parenteral injection formulations used in the acute management of migraine and cluster headache.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Sumatriptan Succinate (CAS 103628-48-4) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Sumatriptan Succinate is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance